Stock Market Reviews

JNJ (Johnson & Johnson) News

Get the latest news, insights, and market updates on JNJ (Johnson & Johnson). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
  ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
  Jan 2, 2026 - $JNJ
• Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026
  NEW BRUNSWICK, N.J., January 02, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.
  Jan 2, 2026 - $JNJ
• Want Decades of Passive Income? 2 Stocks to Buy Right Now
  These income stocks could be great buys to add to your portfolio.
  Jan 1, 2026 - $JNJ
• Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs
  List prices to rise an average of 4% despite federal pressure to curb costs.
  Dec 31, 2025 - $JNJ
• Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
  Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
  Dec 31, 2025 - $JNJ
• Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?
  The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
  Dec 31, 2025 - $JNJ
• BAYRY's 2025 Revival: Will the Momentum Continue in 2026?
  BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.
  Dec 31, 2025 - $JNJ
• Here’s What Analysts Think About Halozyme Therapeutics (HALO)
  Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or […]
  Dec 31, 2025 - $JNJ
• AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share
  AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]
  Dec 31, 2025 - $JNJ
• How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
  BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.
  Dec 31, 2025 - $JNJ